Global English
Global English Global English Poland polski Czechia Český Italy Italiano Kazakhstan Қазақ Slovakia Slovenský Spain Español Russia Pусский Ukraine Українськa Uzbekistan Ўзбекча Vietnam Tiếng việt
Popular searches InnovationsAbout AdamedBusiness DevelopmentAdamed worldwideResearches
x

Information on results RFP 023201_0 TENDER FOR REFERENCE PRODUCTS WITH CoA – RESPI

In connection with the co-financing of the projects:

  1. Project “Development, clinical confirmation of bioequivalence and implementation of a new generation combination ternary inhalation drug in the systematic therapy of COPD”, contract number 2022/ABM/04/00011 – 00
  2. Project  “Development, clinical confirmation of bioequivalence and implementation of a new generation combination inhaled drug in the systematic therapy of COPD”, contract number 2022/ABM/04/00012 – 00
  3. Project “Development, clinical confirmation of bioequivalence and implementation of a new generation complex inhaled drug in the systematic therapy of respiratory diseases Asthma and COPD”, contract number 2022/ABM/04/00013 – 00

financed by the State budget from the Medical Research Agency as part of the Competition for the development of innovative solutions in the area of ​​new pharmaceutical forms of medicinal products authorized for marketing, generic drugs and biosimilars ABM/2022/4, pursuant to § 8 sec. 2 point 2) of the co-financing agreement, Adamed Pharma S.A. informs that the contract will be awarded to the following company that has presented the most advantageous offer:

  • Pro Pharmaceuticals Group.